Cargando…

(18)F-AV1451 PET imaging and multimodal MRI changes in progressive supranuclear palsy

OBJECTIVES: Progressive supranuclear palsy (PSP) is characterized by deposition of straight filament tau aggregates in the grey matter (GM) of deep nuclei and cerebellum. We examined the relationship between tau pathology (assessed via (18)F-AV1451 PET) and multimodal MRI imaging using GM volume, co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nicastro, Nicolas, Rodriguez, Patricia Vazquez, Malpetti, Maura, Bevan-Jones, William Richard, Simon Jones, P., Passamonti, Luca, Aigbirhio, Franklin I., O’Brien, John T., Rowe, James B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2019
Materias:	Original Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6989441/ https://www.ncbi.nlm.nih.gov/pubmed/31641878 http://dx.doi.org/10.1007/s00415-019-09566-9

Ejemplares similares

(18)F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy
por: Passamonti, Luca, et al.
Publicado: (2017)

Molecular pathology and synaptic loss in primary tauopathies: an (18)F-AV-1451 and (11)C-UCB-J PET study
por: Holland, Negin, et al.
Publicado: (2021)

Imaging tau burden in dementia with Lewy bodies using [(18)F]-AV1451 positron emission tomography
por: Mak, Elijah, et al.
Publicado: (2021)

[(18)F]AV‐1451 PET in behavioral variant frontotemporal dementia due to MAPT mutation
por: Bevan Jones, W. Richard, et al.
Publicado: (2016)

Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy
por: Smith, Ruben, et al.
Publicado: (2016)

[(18)F]-AV-1451 binding in the substantia nigra as a marker of neuromelanin in Lewy body diseases
por: Mak, Elijah, et al.
Publicado: (2021)

Neuroinflammation predicts disease progression in progressive supranuclear palsy
por: Malpetti, Maura, et al.
Publicado: (2021)

[(18)F]AV‐1451 binding is increased in frontotemporal dementia due to C9orf72 expansion
por: Bevan‐Jones, Richard W., et al.
Publicado: (2018)

In Vivo (18)F-Flortaucipir PET Does Not Accurately Support the Staging of Progressive Supranuclear Palsy
por: Malpetti, Maura, et al.
Publicado: (2022)

Increased basal ganglia binding of (18) F‐AV‐1451 in patients with progressive supranuclear palsy
por: Smith, Ruben, et al.
Publicado: (2016)

[(18)F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia
por: Bevan-Jones, W R, et al.
Publicado: (2018)

Structural correlates of survival in Progressive Supranuclear Palsy
por: Street, Duncan, et al.
Publicado: (2023)

An autoradiographic evaluation of AV-1451 Tau PET in dementia
por: Lowe, Val J., et al.
Publicado: (2016)

[(11)C]PK11195 binding in Alzheimer disease and progressive supranuclear palsy
por: Passamonti, Luca, et al.
Publicado: (2018)

Quantification of Tau Load Using [(18)F]AV1451 PET
por: Golla, Sandeep S. V., et al.
Publicado: (2017)

An updated radiosynthesis of [(18)F]AV1451 for tau PET imaging
por: Mossine, Andrew V., et al.
Publicado: (2017)

Tau burden and the functional connectome in Alzheimer’s disease and progressive supranuclear palsy
por: Cope, Thomas E, et al.
Publicado: (2018)

(18)F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes
por: Tsai, Richard M., et al.
Publicado: (2019)

Clinical progression of progressive supranuclear palsy: impact of trials bias and phenotype variants
por: Street, Duncan, et al.
Publicado: (2021)

In vivo PET imaging of neuroinflammation in familial frontotemporal dementia
por: Malpetti, Maura, et al.
Publicado: (2021)

Falls in Progressive Supranuclear Palsy
por: Brown, Fraser S., et al.
Publicado: (2019)

Validation of the new pathology staging system for progressive supranuclear palsy
por: Briggs, Mayen, et al.
Publicado: (2021)

Considerations and code for partial volume correcting [(18)F]-AV-1451 tau PET data
por: Baker, Suzanne L., et al.
Publicado: (2017)

Increased retention of tau PET ligand [(18)F]-AV1451 in Alzheimer’s Disease Psychosis
por: Gomar, J. J., et al.
Publicado: (2022)

In vivo retention of (18)F-AV-1451 in corticobasal syndrome
por: Smith, Ruben, et al.
Publicado: (2017)

Gray matter changes related to microglial activation in Alzheimer's disease
por: Nicastro, Nicolas, et al.
Publicado: (2020)

Cortical Complexity Analyses and Their Cognitive Correlate in Alzheimer’s Disease and Frontotemporal Dementia
por: Nicastro, Nicolas, et al.
Publicado: (2020)

The Role of 18F-Flortaucipir (AV-1451) in the Diagnosis of Neurodegenerative Disorders
por: Roy, Saswata, et al.
Publicado: (2021)

(18)F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers
por: Smith, Ruben, et al.
Publicado: (2016)

Increased Uptake of AV-1451 in a Subacute Infarction Lesion
por: Cho, Soo Hyun, et al.
Publicado: (2018)

Microglial activation and tau burden predict cognitive decline in Alzheimer’s disease
por: Malpetti, Maura, et al.
Publicado: (2020)

Neurophysiological consequences of synapse loss in progressive supranuclear palsy
por: Adams, Natalie E, et al.
Publicado: (2022)

Imaging Aβ and tau in early stage Alzheimer’s disease with [(18)F]AV45 and [(18)F]AV1451
por: Firouzian, Azadeh, et al.
Publicado: (2018)

Co‐Occurrence of Apathy and Impulsivity in Progressive Supranuclear Palsy
por: Kok, Zi Q., et al.
Publicado: (2021)

Synaptic density in carriers of C9orf72 mutations: a [(11)C]UCB‐J PET study
por: Malpetti, Maura, et al.
Publicado: (2021)

(18)F-AV-1451 in Parkinson’s Disease with and without dementia and in Dementia with Lewy Bodies
por: Smith, Ruben, et al.
Publicado: (2018)

(18)F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2017)

MAPT rs242557 variant is associated with hippocampus tau uptake on (18)F-AV-1451 PET in non-demented elders
por: Shen, Xue-Ning, et al.
Publicado: (2019)

Influence of common reference regions on regional tau patterns in cross-sectional and longitudinal [(18)F]-AV-1451 PET data
por: Young, Christina B., et al.
Publicado: (2021)

Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer’s disease, frontotemporal dementia and progressive supranuclear palsy
por: Chouliaras, Leonidas, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_62nk4a2q8mj1imtkcpm5ecr7o5